Business, energy, technology, markets and global industry news from Business News Today

ALSFRS-R

PharmaDeviceNews ALSFRS-R
Representative image: Laboratory research into AP-101 highlights AL-S Pharma’s effort to target misfolded SOD1 and advance a potential new treatment approach for amyotrophic lateral sclerosis.
Pharma & Biotech

AL-S Pharma’s AP-101 Phase 2 data strengthen the misfolded SOD1 strategy in ALS

Read how AL-S Pharma’s AP-101 Phase 2 data strengthen the misfolded SOD1 case in ALS and what its Phase 3 trial must prove.

Read More
Pharma & Biotech

Can STATHMIN-2 restoration succeed where ALS therapies have failed? QurAlis data examined

QurAlis ANQUR trial data puts STATHMIN-2 restoration on the ALS map. Find out what changes and what risks remain.

Read More